Welcome to OncologyPRO, the home of Esmo’s educational and scientific resources.

Somatic oncogenic variants and pancytopenia may signal an increased risk of PARP inhibitor-related myeloid neoplasms

Individuals carrying a single nucleotide polymorphism in KCNAB1 may have an increased risk of developing hypertension during bevacizumab therapy

Chemorefractory or relapsed gestational trophoblastic neoplasia may respond to camrelizumab and apatinib treatment

Older patients undergoing cancer treatment are less likely to experience grade 3 or more severe chemotherapy toxicity if given a multidisciplinary assessment during treatment planning

Health-related quality of life and symptom scores are maintained in patients with clear cell renal cell carcinoma taking adjuvant pembrolizumab

 REGISTRI Results Reported For First-line Regorafenib In KIT/PDGFR Wild-Type Metastatic GIST

Plinabulin plus docetaxel survival and safety results support second- or third-line use in non-small-cell lung cancer patients with wild-type EGFR after platinum-based chemotherapy

Ipilimumab–nivolumab given every 12 weeks, instead of every 3 weeks, reduces toxicities in patients with treatment-naïve advanced renal cell carcinoma without compromising efficacy